PHE Study on Value of Novel Immuno-Oncology Treatments Featured in AJMC

A new study by Precision co-authors Andrew Delgado and Jinjoo Shim, along with scientific advisors John Romley and Katherine Batt, assesses the value to society of improved survival from novel immune-oncology treatments. With the data compiled, the study team concluded that there is evidence of substantial survival gains, and thus, social value.

Appearing in the latest American Journal of Managed Care (AJMC), the abstract and study can be found here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.